Wuxi Biologics Inc., of Wuxi city, said the company has been selected by Hang Seng Indexes as a constituent of the Hang Seng HK 35 Index (HSHK35) effective Sept. 10. Hang Seng HK 35 comprises the 35 largest companies listed in Hong Kong market which derive the majority of their sales revenue from areas outside mainland China. It provides a tradable index reflecting the performance of large-cap Hong Kong companies and features low volatility. Read More
HONG KONG – Following a priority review, Astrazeneca plc won approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Tagrisso (osimertinib). The drug is now greenlighted as a first-line treatment in patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Read More
HONG KONG – Shanghai-based biopharmaceutical firm Harbour Biomed Therapeutics Ltd. completed a series B financing of $85 million, "slightly above" its target, with the round led by Singapore's wealth fund GIC Private Ltd. Harbour anticipates more fundraising in 2019. Read More
NEW DELHI – India's vaccine industry is limping to recovery after a number of setbacks in growth in recent months even as some industry experts worry that the domestic sector is losing ground to China and South Korea. Read More
CSL Ltd.'s vaccine business Seqirus expects to roll out real-world findings "in the next few months" that will help show whether and to what degree the cell-based approach to making influenza vaccines is better than the egg-based, said Gordon Naylor, Seqirus' president. Read More
Australian researchers have identified for the first time in decades a previously unknown immune system microstructure, which they have demonstrated to be responsible for immunological memory. This is a key finding, as it may be used to rapidly mobilize secondary antibody responses and improve vaccine efficacy, the researchers wrote in a study published In the Aug. 22, 2018, edition of Nature Communications. Read More
The findings of a Chinese-led international study into regional variations in reference ranges and models of diseases clearly related to dysbiosis in the gut microbiome could have important public health implications for managing disorders including fatty liver and other metabolic diseases. Read More
